알츠하이머병 환자의 뇌 영상 검사의 최신 지견과임상 적용 방법

키워드

참고문헌 (56)

1. Glenner GG, "Alzheimer’s disease : initial report of the purification and characterization of a novel cerebrovascular amyloid protein", Alzheimer Dis Assoc Disord, 2, pp.134~ (1988)
2. Masters CL, "Amyloid plaque core protein in Alzheimer disease and Down syndrome", Proc Natl Acad Sci U S A, 82, pp.4245~4249 (1985)
3. Westman E, "AddNeuroMed consortium; Alzheimer’s Disease Neuroimaging Initiative. AddNeuroMed and ADNI: similar patterns of Alzheimer’s atrophy and automated MRI classification accuracy in Europe and North America", Neuroimage, 58, pp.818~828 (2011)
4. Henneman WJ, "Hippocampal atrophy rates in Alzheimer disease : added value over whole brain volume measures", Neurology, 72, pp.999~1007 (2009)
5. Kantarci K, "Evidence-based imaging: optimizing imaging in patient care", pp.142~159 (2006), Springer
6. Harper L, "Using visual rating to diagnose dementia : a critical evaluation of MRI atrophy scales", J Neurol Neurosurg Psychiatry, 86, pp.1225~1233 (2015)
7. de Leon MJ, "Early marker for Alzheimer’s disease : the atrophic hippocampus", Lancet, 2, pp.672~673 (1989)
8. Scheltens P, "Atrophy of medial temporal lobes on MRI in"probable"Alzheimer’s disease and normal ageing : diagnostic value and neuropsychological correlates", J Neurol Neurosurg Psychiatry, 55, pp.967~972 (1992)
9. Galton CJ, "Temporal lobe rating scale : application to Alzheimer’s disease and frontotemporal dementia", J Neurol Neurosurg Psychiatry, 70, pp.165~173 (2001)
10. Kaneko T, "New visual rating system for medial temporal lobe atrophy : a simple diagnostic tool for routine examinations", Psychogeriatrics, 12, pp.88~92 (2012)
11. Cavallin L, "Overtime reliability of medial temporal lobe atrophy rating in a clinical setting", Acta Radiol, 53, pp.318~323 (2012)
12. Cavallin L, "Comparison between visual assessment of MTA and hippocampal volumes in an elderly, non-demented population", Acta Radiol, 53, pp.573~579 (2012)
13. McKhann G, "Clinical diagnosis of Alzheimer’s disease : report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
14. Barber R, "Medial temporal lobe atrophy on MRI in dementia with Lewy bodies", Neurology, 52, pp.1153~1158 (1999)
15. Pasquier F, "Inter-and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts", Eur Neurol, 36, pp.268~272 (1996)
16. Henneman WJ, "MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population", Stroke, 40, pp.492~498 (2009)
17. Ferreira D, "AddNeuroMed consortium and for the Alzheimer’s Disease Neuroimaging Initiative. Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition", Eur Radiol, 26, pp.2597~2610 (2016)
18. McKhann GM, "The diagnosis of dementia due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.263~269 (2011)
19. Barkhof F, "Neuroimaging in dementia" (2011), Springer Science & Business Media
20. Scheltens P, "Qualitative assessment of cerebral atrophy on MRI : inter-and intra-observer reproducibility in dementia and normal aging", Eur Neurol, 37, pp.95~99 (1997)
21. Koedam EL, "Visual assessment of posterior atrophy development of a MRI rating scale", Eur Radiol, 21, pp.2618~2625 (2011)
22. Lehmann M, "Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer’s disease", Neurobiol Aging, 33(3), pp.627.e1~627.e12 (2012)
23. Inzitari D, "Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes : the LADIS Study", Arch Intern Med, 167, pp.81~88 (2007)
24. Inzitari D, "LADIS Study Group. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort", BMJ, 339, pp.b2477~ (2009)
25. Sokoloff L, "The deoxyglucose method for the measurement of local glucose utilization and the mapping of local functional activity in the central nervous system", Int Rev Neurobiol, 22, pp.287~333 (1981)
26. Jack CR Jr, "Tracking pathophysiological processes in Alzheimer’s disease : an updated hypothetical model of dynamic biomarkers", Lancet Neurol, 12, pp.207~216 (2013)
27. Selkoe DJ, "Alzheimer’s disease is a synaptic failure", Science, 298, pp.789~791 (2002)
28. FDG PET, "Eur J Nucl Med Mol Imaging", 2012, 990~1000
29. Protas HD, "Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease", JAMA Neurol, 70, pp.320~325 (2013)
30. Förster S, "Regional expansion of hypometabolism in Alzheimer’s disease follows amyloid deposition with temporal delay", Biol Psychiatry, 71, pp.792~797 (2012)
31. Mosconi L, "Reduced hippocampal metabolism in MCI and AD : automated FDGPET image analysis", Neurology, 64, pp.1860~1867 (2005)
32. Mosconi L, "Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias", J Nucl Med, 49, pp.390~398 (2008)
33. Hoffman JM, "FDG PET imaging in patients with pathologically verified dementia", J Nucl Med, 41, pp.1920~1928 (2000)
34. Arnáiz E, "Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment", Neuroreport, 12, pp.851~855 (2001)
35. Chételat G, "Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease?", Neurology, 60, pp.1374~1377 (2003)
36. Anchisi D, "Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease", Arch Neurol, 62, pp.1728~1733 (2005)
37. Drzezga A, "Prediction of individual clinical outcome in MCI by means of genetic assessment and(18)F-FDG PET", J Nucl Med, 46, pp.1625~1632 (2005)
38. Minoshima S, "Alzheimer’s disease versus dementia with Lewy bodies : cerebral metabolic distinction with autopsy confirmation", Ann Neurol, 50, pp.358~365 (2001)
39. Foster NL, "FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease", Brain, 130(Pt 10), pp.2616~2635 (2007)
40. Bennett DA, "Neuropathology of older persons without cognitive impairment from two community-based studies", Neurology, 66, pp.1837~1844 (2006)
41. Villemagne VL, "Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study", Lancet Neurol, 12, pp.357~367 (2013)
42. Donohue MC, "Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer’s Disease Neuroimaging Initiative; Alzheimer’s Disease Cooperative Study. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline", JAMA Neurol, 71, pp.961~970 (2014)
43. Lim YY, "Rapid decline in episodic memory in healthy older adults with high amyloid-β", J Alzheimers Dis, 33, pp.675~679 (2013)
44. Klunk WE, "Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain", Life Sci, 69, pp.1471~1484 (2001)
45. flutemetamol positron emission tomography : from dosimetry to clinical diagnosis, "Eur J Nucl Med Mol Imaging", 2016, 362~373
46. Bullich S, "Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment", Neuroimage Clin, 15, pp.325~332 (2017)
47. Landau SM, "Amyloid-βimaging with Pittsburgh compound B and florbetapir : comparing radiotracers and quantification methods", J Nucl Med, 54, pp.70~77 (2013)
48. Villemagne VL, "Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease", Eur J Nucl Med Mol Imaging, 39, pp.983~989 (2012)
49. Curtis C, "Phase 3 trial of flutemetamol labeled with radioactive fluorine 18imaging and neuritic plaque density", JAMA Neurol, 72, pp.287~294 (2015)
50. florbetaben PET study, "Neurology", 2015, 500~507
51. Sabri O, "Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease : Phase 3 Study", Alzheimers Dement, 11, pp.964~974 (2015)
52. Rabinovici GD, "Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD", Neurology, 77, pp.2034~2042 (2011)
53. Siderowf A, "PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133(florbenazine)in patients with Alzheimer’s disease and Lewy body disorders", BMC Neurol, 14, pp.79~ (2014)
54. Jack CR Jr, "Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease", Brain, 133, pp.3336~3348 (2010)
55. PiB, "Neurology", 2010, 807~815
56. Pike KE, "Cognition and beta-amyloid in preclinical Alzheimer’s disease : data from the AIBL study", Neuropsychologia, 49, pp.2384~2390 (2011)

관련 논문AI추천